ST6GAL1 and melanoma: Utilizing ST6Gal1 null mice inoculated with B16-F0 melanoma tumors, it was revealed that α2,6 sialylation was high in tumors sensitive to anti-VEGF monoclonal antibody treatment, and ST6Gal1 knockout also led to protection against anti-VEGF treatment (Croci et al., 2014a).